Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): Preliminary analysis of 6-month data from > 10000 patients and review of the literature

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 5, 2007, Pages

  Shlyakhto, Evgeny ^a  

^a ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

Author keywords

Angiotensin II type 1 receptor blocker (ARB); Cognitive function; Dementia; Eprosartan; Hypertension; Mini mental status examination (MMSE); Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR) trial

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; NITRENDIPINE; PERINDOPRIL;

BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DEMENTIA; HUMAN; HYPERTENSION; MINI MENTAL STATE EXAMINATION; NONHUMAN; OBSERVATIONAL STUDY; RECOMMENDED DRUG DOSE; STROKE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ACRYLATES; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; COGNITION DISORDERS; DEMENTIA, VASCULAR; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RATS; STROKE; THIOPHENES;

EID: 37849041924     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X260719     Document Type: Conference Paper

References (28)

1. Bowler JV. The concept of vascular cognitive impairment. J Neurol Sci 2002;203-204:11-15
2. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89-98
3. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4
4. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5
5. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-6
6. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218-26
7. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359: 995-1003
8. Lithell H, Hansson L, Skoog, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
9. Staessen J, Fagard R, Amery A. Isolated systolic hypertension in the elderly: implications of Systolic Hypertension in the Elderly Program (SHEP) for clinical practice and for the ongoing trials. J Hum Hypertens 1991;5:469-74
10. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51
11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
12. Epstein BJ, Gums JG. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005;25:531-9
13. Richards SS, Emsley CL, Roberts J, et al. The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J Am Geriatr Soc 2000;48:1035-41
14. Farmer ME, White LR, Abbott RD, et al. Blood pressure and cognitive performance. The Framingham Study. Am J Epidemiol 1987;126:1103-14
15. Elias MF, Wolf PA, D'Agostino RB, et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353-64
16. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365-75
17. McGuinness B, Todd S, Passmore P, et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006;:CD004034
18. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 1998;93(Suppl 2):85-91
19. Toblli JE, Cao G, Casas G, et al. NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system. Urol Res 2005;33:358-67
20. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182-91
21. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21
22. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000;35(1 Pt 2):155-63
23. Suzuki G, Mishima T, Tanhehco EJ, et al. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol 2003;138:301-9
24. Landmesser U, Drexler H. Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 2006;24:S39-43
25. Brooks DP, Ohlstein EH, Ruffolo RR, Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999;138(3 Pt 2):246-51
26. Barone FC, Coatney RW, Chandra S, et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 2001;50:525-37
27. Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl 2006;24:S115-21
28. Jonsson L, Lindgren P, Wimo A, et al. Costs of Mini Mental State Examination-related cognitive impairment. Pharmacoeconomics 1999;16:409-16